Search Results - Shujing Ma
- Showing 1 - 7 results of 7
-
1
-
2
Clinical efficacy, safety, and subjective experience based on ePRO in HIV‐infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China by Linghong Kong, Xiaoxin Xie, Yanhua Fu, Lin Gan, Xiaoyan Yang, Shujing Ma, Hai Long
Published in Immunity, Inflammation and Disease (2023-08-01)Get full text
Article -
3
-
4
Childhood body size, adulthood adiposity, underlying mechanisms, and risk of incident hypertension: a prospective cohort study of 180,527 participants by Shujing Ma, Xue Liu, Ruilang Lin, Ye Yao, Min Zhao, Yongfu Yu, Costan G. Magnussen, Bo Xi
Published in BMC Medicine (2025-01-01)Get full text
Article -
5
Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study by Lin Gan, Xiaoxin Xie, Yanhua Fu, Xiaoyan Yang, Shujing Ma, Linghong Kong, Chunli Song, Yebing Song, Tingting Ren, Hai Long
Published in BMC Infectious Diseases (2024-06-01)Get full text
Article -
6
Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study by Lin Gan, Xiaoxin Xie, Yanhua Fu, Xiaoyan Yang, Shujing Ma, Linghong Kong, Chunli Song, Yebing Song, Tingting Ren, Hai Long
Published in Infectious Diseases and Therapy (2023-10-01)Get full text
Article -
7
Efficacy and safety of dolutegravir plus lamivudine for patients with late presentation of HIV-1 infection: a retrospective real-world cohort study in Southwest China by Qing Wang, Xiaoxin Xie, Yanhua Fu, Xiaoyan Yang, Lin Gan, Shujing Ma, Pengzhu Jiao, Muli Wu, Jun Li, Hai Long, Hai Long
Published in Frontiers in Medicine (2025-08-01)Get full text
Article
